Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and Myxoid Liposarcoma

ecteinascidin 743 has been researched along with Myxoid Liposarcoma in 29 studies

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (13.79)29.6817
2010's19 (65.52)24.3611
2020's6 (20.69)2.80

Authors

AuthorsStudies
Casali, PG; Celant, S; Comandone, A; Di Segni, S; Napolitano, A; Olimpieri, PP; Russo, P; Sanfilippo, R; Vincenzi, B1
Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F1
Keung, EZ; Nassif, EF; Somaiah, N; Thirasastr, P1
Ae, K; Fukuda, N; Hayakawa, K; Hayashi, N; Matsumoto, S; Minami, Y; Nakano, K; Ohmoto, A; Oki, R; Ono, M; Saito, M; Sato, Y; Suto, H; Takahashi, S; Tanizawa, T; Tomomatsu, J; Udagawa, S; Urasaki, T; Wang, X; Yunokawa, M1
Alvarez, R; Blay, JY; Casali, PG; Cruz Jurado, J; Dei Tos, AP; Fabbroni, C; Gronchi, A; Gutierrez, A; Hindi, N; Italiano, A; Lopez-Pousa, A; Martin-Broto, J; Morosi, C; Pérez Aguiar, JL; Ranchere-Vince, D; Rincón-Perez, I; Romagosa, C; Romero, J; Sanfilippo, R; Sangalli, C; Sunyach, MP1
Ballabio, S; Bello, E; Brich, S; Carrassa, L; Casali, PG; Craparotta, I; D'Incalci, M; Frapolli, R; Gatta, R; Gronchi, A; Mannarino, L; Marchini, S; Matteo, C; Pilotti, S; Sanfilippo, R1
Ballabio, S; Bello, E; Brich, S; Carrassa, L; Casali, PG; Craparotta, I; D'Incalci, M; Frapolli, R; Gronchi, A; Mannarino, L; Marchini, S; Pilotti, S; Ponzo, M; Porcu, L; Sanfilippo, R; Ubezio, P1
Ballabio, S; Barisella, M; Bello, E; Callari, M; Casali, PG; Craparotta, I; D'Incalci, M; Fabbroni, C; Frapolli, R; Mannarino, L; Marchini, S; Meroni, M; Panini, N; Sanfilippo, R1
Allonca, E; Astudillo, A; Fernandez-Garcia, MT; Garcia-Pedrero, JM; Martinez-Cruzado, L; Rodriguez, A; Rodriguez, R; Santos, L; Tornin, J1
Araki, N; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Shimura, M; Sugiura, H; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T1
Garcia Del Muro, X; Ibrahim, T; Jones, RL; Le Cesne, A; Menge, F1
Abaricia, S; Hirbe, AC1
Assi, T; Dumont, S; El Rassy, E; Honore, C; Kattan, J; Le Cesne, A; Mir, O1
Casali, PG; Sanfilippo, R1
Bello, E; Beltrame, L; Brich, S; Casali, PG; D'Incalci, M; Di Giandomenico, S; Frapolli, R; Galmarini, CM; Gatta, R; Gronchi, A; Grosso, F; Licandro, SA; Mantovani, R; Marchini, S; Mauro, V; Pilotti, S; Sanfilippo, R; Sousa-Faro, JM; Tamborini, E; Uboldi, S1
Allavena, P; Badri, N; D'Incalci, M; Galmarini, CM1
Belotti, D; Borsotti, P; Bozzi, F; Brich, S; Castiglioni, V; D'Incalci, M; Di Giandomenico, S; Dossi, R; Erba, E; Frapolli, R; Giavazzi, R; Marchini, S; Paracchini, L; Pilotti, S; Sanfilippo, R; Taraboletti, G; Uboldi, S1
Aman, P; Casali, P; D'Incalci, M; Erba, E; Forni, C; Gronchi, A; Grosso, F; Mantovani, R; Minuzzo, M; Pilotti, S; Simone, M; Tamborini, E; Tavecchio, M; Virdis, E1
Casali, PG; Collini, P; D'Incalci, M; Dileo, P; Gronchi, A; Grosso, F; Jimeno, J; Morosi, C; Pilotti, S; Piovesan, C; Sanfilippo, R; Tercero, JC; Virdis, E1
Allavena, P; Casali, PG; D'Incalci, M; Erba, E; Frapolli, R; Galmarini, CM; Germano, G; Greco, A; Gronchi, A; Grosso, F; Mantovani, A; Nebuloni, M; Pasqualini, F; Pesce, S; Pilotti, S; Sanfilippo, R; Simone, M; Tarantino, E; Tavecchio, M; Tercero, JC; Virdis, E1
Bozzi, F; Brich, S; Casalini, P; Cassinelli, G; Greco, A; Grosso, F; Jocollè, G; Negri, T; Pierotti, MA; Pilotti, S; Sanfilippo, R; Tamborini, E; Tarantino, E; Virdis, E1
Bello, E; Casali, P; D'Incalci, M; Frapolli, R; Gronchi, A; Grosso, F; Marchini, S; Peloso, G; Pilotti, S; Sanfilippo, R; Tamborini, E; Tarantino, E; Tercero, JC; Virdis, E1
Alfaro, V; Blay, JY; Bonvalot, S; Bui, BN; Demetri, GD; Ferrari, S; Gronchi, A; Hohenberger, P; Hohl, RJ; Lardelli, P; Le Cesne, A; Nieto, A; Pérez, I; Pilotti, S; Tamborini, E; Tercero, JC1
Bernasconi, S; Caccuri, AM; Capozzi, O; Chiorino, G; Clivio, L; D'Incalci, M; Damia, G; Di Giandomenico, S; Erba, E; Fossati, A; Fuso Nerini, I; Ganzinelli, M; Grosso, F; Mantovani, R; Marangon, E; Marchini, S; Margison, GP; Pastore, A; Rocchi, M; Romano, M; Sala, F; Tercero, JC; Uboldi, S; Watson, AJ1
Charytonowicz, E; Coakley, K; Cordon-Cardo, C; Matushansky, I; Remotti, F; Taub, RN; Telis, L; Terry, M1
Beltrame, L; Calura, E; Cavalieri, D; Chiorino, G; D'Angelo, D; D'Incalci, M; Erba, E; Fuso Nerini, I; Marchini, S; Ostano, P; Romualdi, C; Uboldi, S1
Brucato, A; Colombo, T; Dieli, M; Fasolini, G; Ferrazzi, P; Gianatti, A; Gori, M; Medolago, G; Moreo, A; Pedrotti, P; Simon, C1
Blay, JY; Casali, PG; Casieri, P; Collini, P; D'Incalci, M; Demetri, GD; Dileo, P; Fletcher, JA; Gronchi, A; Grosso, F; Jimeno, J; Jones, RL; Judson, IR; Le Cesne, A; Pilotti, S; Sanfilippo, R; Spreafico, C; Stacchiotti, S; Tamborini, E; Tercero, JC1
von Mehren, M1

Reviews

5 review(s) available for ecteinascidin 743 and Myxoid Liposarcoma

ArticleYear
Myxoid Liposarcomas: Systemic Treatment Options.
    Current treatment options in oncology, 2023, Volume: 24, Issue:4

    Topics: Adult; Anthracyclines; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Progression-Free Survival; Trabectedin

2023
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
    Expert review of anticancer therapy, 2018, Volume: 18, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Patient Reported Outcome Measures; Quality of Life; Sarcoma; Trabectedin; Young Adult

2018
Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.
    Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12

    Topics: Antibodies, Monoclonal; Doxorubicin; Furans; Humans; Immunotherapy; Ketones; Liposarcoma, Myxoid; Mesoderm; Protein-Tyrosine Kinases; Trabectedin

2018
A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
    Cancer treatment reviews, 2019, Volume: 72

    Topics: Antineoplastic Agents, Alkylating; Humans; Liposarcoma, Myxoid; Trabectedin

2019
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Liposarcoma, Myxoid; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic; Tumor Microenvironment

2014

Trials

2 trial(s) available for ecteinascidin 743 and Myxoid Liposarcoma

ArticleYear
Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
    The oncologist, 2017, Volume: 22, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liposarcoma, Myxoid; Male; Middle Aged; Neoplasm Staging; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2017
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Liposarcoma, Myxoid; Male; Middle Aged; Neoadjuvant Therapy; Tetrahydroisoquinolines; Trabectedin; Young Adult

2012

Other Studies

22 other study(ies) available for ecteinascidin 743 and Myxoid Liposarcoma

ArticleYear
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
    International journal of cancer, 2023, 02-15, Volume: 152, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Registries; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin

2023
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
    Oncology, 2022, Volume: 100, Issue:12

    Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin

2022
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study.
    PloS one, 2023, Volume: 18, Issue:3

    Topics: Adult; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin

2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
    JAMA oncology, 2023, 05-01, Volume: 9, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Female; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms; Trabectedin

2023
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
    British journal of cancer, 2019, Volume: 121, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbolines; Carrier Proteins; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Heterocyclic Compounds, 4 or More Rings; Humans; Liposarcoma, Myxoid; Mice; Mice, Nude; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-15, Volume: 25, Issue:24

    Topics: Adipocytes; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Liposarcoma, Myxoid; Mice; Mice, Nude; Pioglitazone; PPAR gamma; Trabectedin; Xenograft Model Antitumor Assays

2019
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
    Genomics, 2021, Volume: 113, Issue:5

    Topics: Adult; Animals; Disease Models, Animal; Humans; Liposarcoma, Myxoid; Mice; Trabectedin

2021
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
    Neoplasia (New York, N.Y.), 2017, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Dioxoles; DNA Damage; Drug Synergism; Humans; Liposarcoma; Liposarcoma, Myxoid; Mice; Neoplastic Stem Cells; Signal Transduction; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays

2017
The intriguing patterns of tumor response to trabectedin.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:6 Suppl 1

    Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tumor Microenvironment; Uterine Neoplasms

2013
Mode of action of trabectedin in myxoid liposarcomas.
    Oncogene, 2014, Oct-30, Volume: 33, Issue:44

    Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Biopsy; Cell Differentiation; Dioxoles; Doxorubicin; Female; Humans; Liposarcoma, Myxoid; Mice, Nude; Oncogene Proteins, Fusion; RNA-Binding Protein FUS; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP; Xenograft Model Antitumor Assays

2014
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    International journal of cancer, 2015, Feb-01, Volume: 136, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; CCAAT-Enhancer-Binding Protein-beta; Cells, Cultured; Dioxoles; Endothelial Cells; Female; Humans; Liposarcoma, Myxoid; Mice; Mice, Inbred C57BL; Tetrahydroisoquinolines; Thrombospondin 1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Trabectedin

2015
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:2

    Topics: Adipogenesis; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell Line, Tumor; Dioxoles; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Liposarcoma, Myxoid; Male; Middle Aged; Oncogene Proteins, Fusion; Protein Binding; RNA-Binding Protein FUS; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP

2009
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposarcoma, Myxoid; Male; Middle Aged; Retrospective Studies; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Trabectedin

2009
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Cancer research, 2010, Mar-15, Volume: 70, Issue:6

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; C-Reactive Protein; Cell Cycle; Cell Death; Cell Line, Tumor; Chemokine CCL2; Dioxoles; Humans; Immunohistochemistry; Inflammation Mediators; Interleukin-6; Interleukin-8; Liposarcoma, Myxoid; Macrophages; Mice; Serum Amyloid P-Component; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Dioxoles; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Liposarcoma, Myxoid; Male; Microscopy, Confocal; Middle Aged; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrahydroisoquinolines; Trabectedin

2010
Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Cell Growth Processes; Dioxoles; Female; Humans; In Situ Hybridization, Fluorescence; Liposarcoma, Myxoid; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Tetrahydroisoquinolines; Trabectedin; Transplantation, Heterologous

2010
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Dacarbazine; Dioxoles; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibronectins; Humans; Liposarcoma, Myxoid; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA-Binding Protein FUS; Serum Amyloid P-Component; Signal Transduction; Temozolomide; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP; Tumor Suppressor Proteins; Ultraviolet Rays

2012
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:3

    Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Cell Differentiation; Dioxoles; Disease Models, Animal; Drug Synergism; Female; Humans; Liposarcoma, Myxoid; Male; Mice; Mice, Transgenic; Middle Aged; Neoplasm Transplantation; PPAR gamma; Tetrahydroisoquinolines; Trabectedin

2012
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dioxoles; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Liposarcoma, Myxoid; MicroRNAs; Neoplasm Proteins; RNA, Messenger; Systems Biology; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic

2012
Jellyfish in the heart.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Adult; Antineoplastic Agents; Dioxoles; Echocardiography; Heart Neoplasms; Humans; Liposarcoma, Myxoid; Magnetic Resonance Imaging; Male; Multimodal Imaging; Positron-Emission Tomography; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome

2013
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    The Lancet. Oncology, 2007, Volume: 8, Issue:7

    Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Liposarcoma, Myxoid; Magnetic Resonance Imaging; Male; Middle Aged; Oncogene Proteins, Fusion; Retrospective Studies; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin

2007
Trabectedin--a targeted chemotherapy?
    The Lancet. Oncology, 2007, Volume: 8, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Liposarcoma, Myxoid; Oncogene Proteins, Fusion; Tetrahydroisoquinolines; Trabectedin

2007